These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23374028)

  • 41. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New aerosol delivery devices for cystic fibrosis.
    Kesser KC; Geller DE
    Respir Care; 2009 Jun; 54(6):754-67; discussion 767-8. PubMed ID: 19467162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
    Saiman L
    Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.
    Zemanick ET; Harris JK; Conway S; Konstan MW; Marshall B; Quittner AL; Retsch-Bogart G; Saiman L; Accurso FJ
    J Cyst Fibros; 2010 Jan; 9(1):1-16. PubMed ID: 19833563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bringing new treatments to the bedside in cystic fibrosis.
    Brennan AL; Geddes DM
    Pediatr Pulmonol; 2004 Feb; 37(2):87-98. PubMed ID: 14730652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.
    Fusco NM; Toussaint KA; Prescott WA
    Ann Pharmacother; 2015 Apr; 49(4):458-68. PubMed ID: 25583881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.
    Ashlock MA; Olson ER
    Annu Rev Med; 2011; 62():107-25. PubMed ID: 21226613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pipeline of therapies for cystic fibrosis.
    Ashlock MA; Beall RJ; Hamblett NM; Konstan MW; Penland CM; Ramsey BW; Van Dalfsen JM; Wetmore DR; Campbell PW
    Semin Respir Crit Care Med; 2009 Oct; 30(5):611-26. PubMed ID: 19760548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhaled antibiotics in cystic fibrosis: a review.
    Toso C; Williams DM; Noone PG
    Ann Pharmacother; 1996; 30(7-8):840-50. PubMed ID: 8826569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel pharmaceutical approaches for treating patients with cystic fibrosis.
    Saeed Z; Wojewodka G; Marion D; Guilbault C; Radzioch D
    Curr Pharm Des; 2007; 13(31):3252-63. PubMed ID: 18045175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cystic fibrosis year in review 2019: Section 1 CFTR modulators.
    Savant AP; McColley SA
    Pediatr Pulmonol; 2020 Dec; 55(12):3236-3242. PubMed ID: 32833326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
    Horsley AR; Davies JC; Gray RD; Macleod KA; Donovan J; Aziz ZA; Bell NJ; Rainer M; Mt-Isa S; Voase N; Dewar MH; Saunders C; Gibson JS; Parra-Leiton J; Larsen MD; Jeswiet S; Soussi S; Bakar Y; Meister MG; Tyler P; Doherty A; Hansell DM; Ashby D; Hyde SC; Gill DR; Greening AP; Porteous DJ; Innes JA; Boyd AC; Griesenbach U; Cunningham S; Alton EW
    Thorax; 2013 Jun; 68(6):532-9. PubMed ID: 23396354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.
    Haack A; Aragão GG; Novaes MR
    World J Gastroenterol; 2013 Dec; 19(46):8552-61. PubMed ID: 24379572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
    Paterson SL; Barry PJ; Horsley AR
    Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
    [No Abstract]   [Full Text] [Related]  

  • 60. Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.
    Goralski JL; Davis SD
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S66-73. PubMed ID: 26335956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.